Beam Therapeutics Inc. Common Stock (BEAM)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.22, providing financial flexibility
• Altman Z-Score of 7.4 confirms minimal bankruptcy risk and strong solvency
• Superior net profit margin of 149.0% indicating pricing power and operational efficiency
• Revenue growth of 279.5% demonstrates strong top-line momentum

AI Analysis

Beam Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $3.2 billion. The business generates $164 million in annual revenue with a 149.0% net margin. From a quality standpoint, Beam shows Altman Z-Score of 7.4 confirms fortress-level solvency and negative ROE indicating losses. Growth dynamics show revenue growing at 279.5% and profit growth of 370.4%. Our composite FairStock Score of 52/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Beam's 280% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer